I-Mab (NASDAQ:IMAB) said on Thursday that it has signed an agreement to acquire Bridge Health Biotech. As part of the deal, I-Mab will provide an initial payment of $1.8M to Bridge Health shareholders ...

Over 30 million people in Europe live with a rare disease. Most of them still lack access to accurate diagnosis or treatment ...

Brisbane-based biotech company Eclipse Ingredients has launched publicly with $7.2 million in funding after navigating a long ...

Regulatory upheaval in the US and a venture capital drought are dampening investor appetites, but there are still diamonds in ...

The new space is a free community service meant to help healthcare entrepreneurs connect with potential funders.

Gujarat becomes the first state in India to initiate a pioneering Tribal Genome Sequencing Project, aimed at improving ...

As measles cases surge to record levels in the U.S., Health and Human Services Secretary Robert F. | As measles cases surge ...

The United Kingdom is establishing a new biosecurity center designed to improve research into potentially pandemic-causing ...

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future ...

USA Health has announced a new technology to help treat tumors due to liver cancer. The treatment, innovative in many ways, is being called a game changer by doctors.

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

For instance, "the backlog of FOIAs ... is enormous," he said. Califf said the FDA has far greater opportunities for improved ...